Suppr超能文献

[抗程序性死亡蛋白1(帕博利珠单抗)治疗下的一种罕见消化系统并发症]

[An unusual digestive complication under anti-PD-1 (pembrolizumab)].

作者信息

Calvani Julien, Elia Rémie, Battistella Maxime, Delyon Julie, Vivier-Chicoteau Justine, Gornet Jean-Marc, Lebbé Céleste, Baroudjian Barouyr, Bertheau Philippe

机构信息

Département de pathologie, université de Paris, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.

Département de pathologie, université de Paris, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.

出版信息

Ann Pathol. 2020 Jul;40(4):320-323. doi: 10.1016/j.annpat.2020.02.001. Epub 2020 Feb 24.

Abstract

The most commonly reported pattern of anti-PD-1 induced colitis is an active colitis characterized by neutrophilic inflammation and prominent apoptosis. On the other hand, reports of collagenous colitis (which is a microscopic colitis) are exceptional. In this report, we describe an unusual case of anti-PD1-associated collagenous colitis in a 76-year-old man, treated with pembrolizumab for a stage IV cutaneous melanoma. Fourteen months after the start of pembrolizumab, the patient developed a grade 3 diarrhea (up to 9 stools per day) associated with profound hypokalemia. No bacterial, viral or parasitological infectious agents were found from stool analysis. The rectosigmoidoscopy showed colonic diffuse congestion with no ulceration. Systematic biopsies were performed during endoscopy. Histologically, the fragments analyzed revealed a moderately thickened subepithelial collagen layer (20-30μm thick) associated with a mild mixed inflammatory infiltrate within the lamina propria. There were no granuloma lesions, ulcerations or viral inclusion bodies. The patient was initially successfully treated with corticosteroids (prednisone) and temporary interruption of pembrolizumab. However, during corticosteroids tapering, a relapse was observed. The treatment was switched to budesonide, leading to a complete and definitive resolution of diarrhea. To date, budesonide has been stopped and pembrolizumab has not been restarted. Currently, there is a bone progression treated by radiotherapy alone. In case of a more important progression, a systemic treatment will be secondarily discussed.

摘要

最常报告的抗程序性死亡蛋白1(PD-1)诱导的结肠炎模式是一种以中性粒细胞炎症和显著凋亡为特征的活动性结肠炎。另一方面,胶原性结肠炎(一种显微镜下结肠炎)的报告则较为罕见。在本报告中,我们描述了一例76岁男性的抗PD-1相关胶原性结肠炎的罕见病例,该患者因IV期皮肤黑色素瘤接受帕博利珠单抗治疗。帕博利珠单抗开始治疗14个月后,患者出现3级腹泻(每天多达9次大便),伴有严重低钾血症。粪便分析未发现细菌、病毒或寄生虫感染病原体。直肠乙状结肠镜检查显示结肠弥漫性充血,无溃疡。在内镜检查期间进行了系统性活检。组织学上,分析的切片显示上皮下胶原层中度增厚(20 - 30μm厚),固有层内有轻度混合性炎症浸润。没有肉芽肿病变、溃疡或病毒包涵体。患者最初成功接受了皮质类固醇(泼尼松)治疗,并暂时中断了帕博利珠单抗治疗。然而,在逐渐减少皮质类固醇剂量期间,观察到病情复发。治疗改为布地奈德,腹泻得以完全且最终缓解。迄今为止,布地奈德已停用,帕博利珠单抗尚未重新开始使用。目前,仅通过放疗治疗骨转移。如果出现更严重的进展,将进一步讨论全身治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验